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Abstract
Background: Chemoradiotherapy (CRT) remains one of the most common cancer treatment modalities, and recent
data suggest that CRT is maximally effective when there is generation of an anti-tumoral immune response.
However, CRT has also been shown to promote immunosuppressive mechanisms which must be blocked or
reversed to maximize its immune stimulating effects.
Methods: Therefore, using a preclinical model of human papillomavirus (HPV)-associated head and neck squamous
cell carcinoma (HNSCC), we developed a clinically relevant therapy combining CRT and two existing
immunomodulatory drugs: cyclophosphamide (CTX) and the small molecule inducible nitric oxide synthase (iNOS)
inhibitor L-n6-(1-iminoethyl)-lysine (L-NIL). In this model, we treated the syngeneic HPV-HNSCC mEER tumor-bearing mice
with fractionated (10 fractions of 3 Gy) tumor-directed radiation and weekly cisplatin administration. We compared the
immune responses induced by CRT and those induced by combinatory treatment (CRT + CTX/L-NIL) with flow cytometry,
quantitative multiplex immunofluorescence and by profiling immune-related gene expression changes.
Results: We show that combination treatment favorably remodels the tumor myeloid immune microenvironment
including an increase in anti-tumor immune cell types (inflammatory monocytes and M1-like macrophages) and a
decrease in immunosuppressive granulocytic myeloid-derived suppressor cells (MDSCs). Intratumoral T cell infiltration and
tumor antigen specificity of T cells were also improved, including a 31.8-fold increase in the CD8+ T cell/ regulatory T cell
ratio and a significant increase in tumor antigen-specific CD8+ T cells compared to CRT alone. CTX/LNIL
immunomodulation was also shown to significantly improve CRT efficacy, leading to rejection of 21% established tumors
in a CD8-dependent manner.
Conclusions: Overall, these data show that modulation of the tumor immune microenvironment with CTX/L-NIL
enhances susceptibility of treatment-refractory tumors to CRT. The combination of tumor immune microenvironment
modulation with CRT constitutes a translationally relevant approach to enhance CRT efficacy through enhanced
immune activation.
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Background
Head and neck squamous cell carcinoma (HNSCC) is
the 6th most common cancer worldwide and has a poor
prognosis at advanced stages of disease [1]. Human pap-
illomavirus (HPV)-associated cancer of the oropharynx
(throat) has become the fastest-increasing HNSCC sub-
type in the US and other developed countries, with the
HPV16 viral type accounting for roughly 80% of
HPV-positive HNSCC (HPV-HNSCC) [2]. Transform-
ation of epithelial cancer cells by HPV16 depends on
expression of the onco-viral proteins, E6 and E7 [3],
which have also been shown to enhance intratumoral
CD8+ T cell infiltration [4]. This enhanced immune
response likely contributes to improved response and
survival rates of HPV-HNSCC after chemoradiotherapy
(CRT) compared to HPV-negative HNSCC [5] highlight-
ing the potential role of tumor immune microenviron-
ment as a determinant of CRT treatment response.
The standard-of-care CRT, consisting of tumor-directed
radiotherapy and concurrent platinum-based chemother-
apy (cisplatin or carboplatin) [6], is highly effective for the
majority of primary HPV-HNSCC patients, but exhibits
high failure rates in patients with locoregionally advanced,
and recurrent or metastatic disease [7, 8]. Increasing
evidence suggests that CRT simultaneously induces pro-
and anti-tumoral immune responses [9]. CRT reportedly
favors a number of anti-tumor mechanisms such as (i)
improved antigen cross-presentation, (ii) increased Type I
interferon release, and (iii) enhanced major histocompati-
bility complex (MHC) class I expression on tumor cells
[10, 11]. However, it has also been linked to a variety of
immunosuppressive effects including (i) the development
of chemotherapy-resistant regulatory T cells (Tregs) [12],
(ii) increased levels of circulating MDSCs (iii) the deple-
tion and exhaustion of tumor-reactive T cells [13], and (iv)
inhibition of T cell reactivity [14]. The multi-faceted
immunomodulatory effects induced by CRT are limiting
factors in its ability to stimulate effective immunological
responses against solid tumors. Thus, immunomodulation
of the tumor microenvironment is a promising approach
to enhance the efficacy of CRT in solid tumors.
During cancer development, the tumor-mediated aber-
rant expression of inflammatory molecules contributes
to the induction and intratumoral infiltration of im-
munosuppressive cells, such as MDSCs and Tregs. One
such inflammatory mediator, inducible nitric oxide syn-
thase (iNOS), is highly upregulated in numerous solid
tumors [15, 16], and favors tumor growth through the
enhanced induction and recruitment of MDSCs [17].
iNOS inhibition, such as with the iNOS-selective small
molecule inhibitor L-n6-(1-iminoethyl)-lysine (L-NIL)
[18] which has previously been tested in clinical trials
for asthma and inflammatory disease [19], induces both
immune-dependent and independent anti-tumor effects.
However, we have demonstrated that iNOS inhibition also
increases Treg development and suppressive function
[20]. To address this, we determined that cyclophospha-
mide (CTX) is an ideal complement to iNOS inhibition
due to its ability to deplete Tregs [21]. Additionally, CTX
enhances T cell activity and specificity by changing the T
cell receptor (TcR) clonality [22–24]. We further demon-
strated that the therapeutic combination of CTX with
L-NIL decreases intratumoral MDSC and Treg levels and
increases CD8+ T cell infiltration [20], leading to enhanced
anti-tumor effects. This suggests that the combination of
CTX/LNIL can positively re-condition the tumor immune
microenvironment, with the potential to enhance the effi-
cacy of other therapeutic regimens, such as CRT. We
therefore hypothesized that adjuvant CTX/L-NIL could
reverse the hostile tumor microenvironment, thereby
enhancing the immunologic benefit of CRT.
To test this hypothesis, we used a syngeneic murine
tumor model of HPV-HNSCC (mEER) featuring murine
pharyngeal epithelial cells transformed with HPV16 E6 and
E7 oncogenes and H-ras [25]. The mEER tumor model was
chosen because its response to CRT has previously been
shown to depend on an intact immune response [26] and it
contains viral antigens (HPV16 E6/E7) suitable for monitor-
ing antigen-specific T cell responses. Herein, we show that,
while CTX/L-NIL or CRT alone induce modest tumor
regression their combination significantly improved treat-
ment efficacy, leading to an average of 21% complete tumor
rejection in a CD8+ T cell-dependent manner. This
enhanced response was attributed to significant improve-
ment in the tumor immune microenvironment including
(i) favorable alterations in the tumor myeloid compartment,
(ii) an increase in the ratio of CD8+ T cells/ Tregs and (iii)
increased infiltration of HPV16 E7-specific CD8+ T cells.
These results suggest that modulation of the tumor
immune microenvironment is an effective approach to
improve treatment efficacy of conventional CRT in
HPV-HNSSC and other solid tumors.
Methods
Mice
C57BL/6 J male mice were purchased from The Jackson
Laboratory and housed under specific pathogen-free
conditions in standard temperature and lighting condi-
tions with free access to food and water. Tumor inocula-
tion was performed when mice reached 8–10 weeks of
age. All experiments were performed with approval of
the Institutional Animal Care and Use Committee
(IACUC) at Baylor College of Medicine (BCM) and
followed established protocols.
Tumor models
MEER tumor cell line expressing HPV16 E6, E7 and
hRas was obtained from Dr. Chad Spanos at the Sanford
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Research center/ University of South Dakota and main-
tained in E-media as previously described [26]. C57BL/6
J mice were injected subcutaneously (s.c.) with 106
mEER cells in the flank.
MOC2 cell line was a generous gift from Dr. Ravindera
Uppaluri at Brigham and Women’s Hospital/ Harvard
Medical School and maintained as previously described
[27]. C57BL/6 J mice were injected subcutaneously (s.c.)
with 15X104 MOC2 cells in the flank.
Mice were monitored twice a week for tumor growth.
Measurements were performed by using calipers and
tumor area (mm2) is expressed as L x W, where L is
Length and W is Width. Growth curve experiments
were stopped once tumors reached 225 mm2.
In vivo treatment
All mice were randomized prior to treatment. Once tu-
mors become established (average tumor size of 65 mm2
or 19mm2, day 17–18 or 8 after mEER and MOC2 in-
oculation, respectively) treatment was initiated over two
weeks. The chemoradiotherapy treatment combined a
fractionated tumor-directed radiation regimen (10 X
3Gy daily) (see Supplementary Material for further de-
tails) with weekly cisplatin (83μg/mouse; Selleck Chemi-
cals) intraperitoneal injections. The immunomodulatory
treatment combined weekly intraperitoneal injections of
cyclophosphamide (2 mg/mouse; TCI Chemicals) and
continuous oral administration of L-NIL (0.2%; Enzo
Life Sciences) in the drinking water ad libitum.
For CD8 depletion experiments, all mice received the
combinatory treatment and were injected with 1mg
depleting InVivoMAb anti-mouse CD8α (clone 53–6.7;
BioXCell) or InVivoMAb rat IgG2a isotype control
(clone 2A3; BioXCell) 2 days prior the treatment, and
further treated with weekly 250 μg antibodies for 3 con-
secutive weeks.
Human primary tumor Immunophenotyping
The 9 patients included in this study were part of a
larger (N = 51) published cohort of HPV+ OPSCC pa-
tients [28, 29]. All 9 patients included in this study re-
ceived standard-of-care adjuvant (chemo) radiotherapy
following surgical resection of their primary tumor. An
overview of patient characteristics and treatments
received is available in the prior publication [29].
Patients were involved after signing informed consent
and studies were conducted in accordance with the Dec-
laration of Helsinki and approved by the local medical
ethical committee of the Leiden University Medical
Center (LUMC) and in agreement with the Dutch law.
Following tumor resection, high-dimensional single
cell mass cytometry (cyTOF) analysis and functional
studies were performed to analyze immune cell popula-
tion tumor infiltration and cytokine of the general tumor
infiltrating lymphocyte. The tumor microenvironment
was reanalyzed for the relative low and strong presence
of immune cell phenotypes and grouped according to the
presence (immune response positive (IR+)) or absence
(immune response negative- (IR-)) of HPV16-specific T
cell tumor infiltration [28, 29].
Flow cytometry
To characterize tumor immune cell infiltration, mEER
tumors were harvested, digested and stained using the
method previously described [30]. Briefly, tumors were
digested in RPMI 1640 (Sigma-Aldrich) containing
DNase I (20 U/ml; Sigma-Aldrich), Collagenase I (1 mg/
ml; EMD Millipore) and Collagenase IV (250 U/ml;
Worthington Biochemical Corporation) prior to mech-
anical disaggregation to form single cell suspensions.
Following digestion, tumor infiltrating leukocytes were
enriched using Lymphoprep™ (STEMCELL Technolo-
gies). Single cell suspensions were also prepared from
tumor-draining inguinal lymph node and spleen with
additional lysis of splenic red blood cells (RBC) using
RBC lysis buffer (Invitrogen). Leukocytes were blocked
with anti-mouse CD16/CD32 Fc block (BD Biosciences)
and stained using one of various antibody panels
(Additional file 1: Table S1 and S2). The viability of
cells was determined using LIVE/DEAD™ Fixable Blue
Dead Cell Stain Kit (Invitrogen). For intracellular staining,
cells were fixed and permeabilized with Intracellular
Fixation and Permeabilization Buffer Set (eBioscience)
and stained using the appropriate antibody panel
(Additional file 1: Table S1). Data were acquired on a
LSRII and LSR Fortessa (BD Biosciences) flow cytometers,
for myeloid and T cell panels respectively, and analyzed
using FlowJo v10 software (FlowJo, LLC).
Quantitative multiplex immunofluorescence
Sectioning and Staining: After harvesting, tumors were
immediately fixed overnight in 10% neutral-buffered for-
malin. Fixed tumors were embedded in paraffin and
sections were cut at a thickness of 5 μm. Full-section
slides of tumor tissues were stained using Opal multi-
plex 6-plex kits, according to the manufacturer’s
protocol (PerkinElmer), for DAPI, Epcam (polyclonal;
Abcam, 1:100 dilution), CD3 (clone SP7; Spring Biosci-
ences; 1:100 dilution), CD8 (clone 4SM15; Thermo-
Fisher; 1:500), CD4 (clone 4SM95; eBioscience, 1:50),
Foxp3 (polyclonal; ThermoFisher, 1:500), and Granzyme
B (polyclonal; Abcam, 1:200). Single color controls and
an unstained slide were also included.
Multispectral imaging and analysis: Multispectral image
capture was done at 20X magnification using Vectra
(PerkinElmer, Hopkinton, MA). Images were analyzed
using inForm software version 2.4.1 (PerkinElmer) as
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previously described [31]. Further details are presented in
the Supplementary Materials.
Gene expression analysis
Tumor samples were harvested and flash frozen in liquid
nitrogen. Total RNA was extracted with the RNeasy
Mini Kit (Qiagen) as per the manufacturer’s instructions.
Gene expression profiling was performed on 100 ng
RNA using the nCounter® PanCancer Immune Profiling
Panel (NanoString Technologies, Inc) containing 770
genes involved in cancer immune response. Further
details are presented in the Additional file 1.
In vitro CD8+ T cell cytotoxicity assay
To observe whether changes in the tumor myeloid com-
partment after treatment influence intratumoral CD8+ T
cell cytotoxicity, CD8+ T cells were purified from the
spleen of naïve C57BL/6 J mice with a magnetic
bead-based CD8+ T cell negative selection kit (Miltenyi
Biotec) and CD11b+/CD11c+ cells were isolated from
mEER tumors undergoing treatment using a magnetic
bead-based CD11c and CD11b positive selection kit
(Miltenyi Biotec). 105 CD8+ T cells were co-cultured
with 3X104 CD11b+/CD11c+ cells in enriched DMEM
(20% FBS, 2 mML-glutamine, 1% non-essential amino
acid, 1 mM sodium pyruvate, 50 nM 2-mercaptoethanol,
1% penicillin/ streptomycin; as previously described
[32]) including 10 ng/ml IL-2 (BioLegend), 2 μg/ml
anti-CD3 (clone: 145-2C11; BioLegend) and 5 μg/ml
anti-CD28 (clone: 37.51; BioLegend). After 4 days of
co-culture, CD8+ T cells were collected and co-cultured
with 3X103 mEER tumor cells at a ratio of 4:1 (CD8+ T
cell: tumor) in enriched DMEM including IL-2 (10 ng/
ml). After 24 h, tumor cell apoptosis was observed via
Cytation Cell Imaging Reader (Biotek) and quantified via
flow cytometry using an Annexin V/Dead Cell Apoptosis
kit (Invitrogen).
Statistical analysis
Data sets were tested for Gaussian distribution using the
D’Agostino-Pearson normality test. For parametric data
sets, statistical significance was determined by: unpaired
t test for two-tailed data and ANOVA test followed by
selected comparison by Tukey’s multiple comparison tests
with multiple comparison correction. For non-parametric
data sets, statistical significance was determined by:
Mann-Whitney test for two tailed data and Kruskal-Wallis
test followed by selected comparison by Dunn’s multiple
comparison tests with multiple comparison correction.
Survival was analyzed by the Kaplan– Meier method using
Log-rank test. (*p < 0.05; **p < 0.01; ***p < 0.001; ****p <
0.0001; ns, non-significant). Outliers from flow cytometry
analysis were determined using ROUT (Q= 1%) method.
Results
Tumor immune microenvironment remains “cold”
following CRT
The immunosuppressive effects of CRT and attempts to
overcome them have been well documented [33, 34];
however, development of immunomodulatory strategies
capable of reversing the balance of CRT immune effects
towards activation remains a critical need. To address
this, we developed an immunomodulatory strategy
capable of rendering the tumor immune microenviron-
ment susceptible to CRT through a “cold” to a “hot” im-
munologic transition (Fig. 1, Additional file 1: Figure S1).
In this study, immunologically “cold” tumors are best
characterized by high immunosuppressive cell infiltrate
(i.e. MDSC, Tregs), low anti-tumor immune cell infiltrate
(CD8+ T cells, M1 macrophages, dendritic cells (DCs)),
and a lack of immune-favorable gene expression. Alterna-
tively, immunologically “hot” tumors present with favor-
able effector/suppressor immune cell ratios and evidence
of anti-tumor immune activation.
To better understand the immune impact of CRT on
the tumor immune microenvironment, we developed a
clinically relevant treatment schedule based on the
standard-of-care CRT regimen for HPV-HNSCC. Briefly,
fractionated tumor-directed radiation (3 Gy X 10 frac-
tions of radiation) was combined with weekly cisplatin
for a total of 2 weeks (Fig. 1a). mEER cells were inocu-
lated subcutaneously in the flank of mice and treatment
was initiated once the established tumor reached
approximately 65 mm2 in size. CRT treatment of tumors
induced modest decreases in tumor growth (Fig. 1b) and
improvement in survival (Fig. 1c). Tumor gene expres-
sion analysis indicates that the tumor microenvironment
remains immunologically “cold” at the midpoint of treat-
ment (one week; Fig. 1f ). Multiple immunologic gene
sets commonly associated with anti-tumor responses
(i.e. T cell and dendritic cell (DC) function, interleukins
(ILs), antigen processing, MHC, chemokines and recep-
tors) showed low levels of expression similar to those of
untreated tumors (Fig. 1f ).
Immune-responsive HPV16+ HNSCC human tumors
display a “hot” immune microenvironment and improved
treatment response
Based on the murine gene expression analysis we next
assessed, in a cohort of human HPV16+ oropharyngeal
squamous cell carcinoma (OPSCC) patients, whether a fa-
vorable tumor immune microenvironment could influence
standard-of-care treatment benefit (Fig. 1d). Briefly, the 9
patients included in this study received standard-of-care
(chemo) radiotherapy following surgical resection of their
primary tumor. Patients were grouped based on the pres-
ence (immune response positive (IR+)) or absence (im-
mune response negative- (IR-)) of HPV16-specific T cell
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Fig. 1 (See legend on next page.)
Hanoteau et al. Journal for ImmunoTherapy of Cancer            (2019) 7:10 Page 5 of 19
tumor infiltration observed prior to treatment as previously
described [28, 29]. In a prior study, IR+ OPSCC patients
treated with surgery followed by adjuvant CRT were shown
to have a 3-fold improvement in 5-year survival compared
to IR- (ca. 90% vs 30%) [28, 29]. In our study, immune cell
type analysis showed that the immune microenvironment
of non-responsive (IR-) tumors was “cold” compared to
that of immune-responsive (IR+) OPSCCs. IR+ tumors
showed increased levels of several immune-stimulating
myeloid subsets (i.e. dendritic cells and M1 macrophages)
and effector lymphoid subsets (i.e. effector memory CD8+
T cells and Th1), thus linking quality of innate and
adaptive intratumoral responses to treatment benefit
(Fig. 1d). Together, these observations suggest that
modulation of the tumor immune microenvironment
to an immune responsive phenotype could increase
the efficacy of standard-of-care CRT treatment.
CTX/LNIL immunomodulation reconditions the
unfavorable tumor immune microenvironment
To activate the tumor immune microenvironment, we
utilized an immunomodulatory treatment previously
developed by our group [20] combining weekly CTX in-
jections with continuous delivery of the iNOS inhibitor,
L-NIL, in drinking water (Additional file 1: Figure S1A).
To first characterize the immunomodulatory effects of
the CTX/LNIL regimen in murine tumors, gene expres-
sion analysis was used to study the effects of each com-
ponent of the treatment. Principal component analysis
(PCA) revealed aggregate differences in gene expression
and clustering based on treatment component (Add-
itional file 1: Figure S1B; PC1 explained 54.13% and PC2
explained 14.25% of the observed variance). Immune
gene-set analysis further revealed a “cold to hot” im-
munologic transition of the tumor following CTX and
CTX/LNIL treatments (Additional file 1: Figure S1C).
This dataset and existing literature [23, 35] support the
notion that CTX treatment induces favorable immuno-
modulatory effects. Nevertheless, its combination with
L-NIL further enhances immune activation and favors a
unique immunologic gene-set upregulation including
STING, innate response, and Th1. Further immune cell
type enrichment analysis revealed gene signatures
consistent with increases in favorable myeloid and
lymphoid subsets following CTX and CTX/LNIL treat-
ment (Additional file 1: Figure S1D). Interestingly, CTX/
LNIL promoted significant enrichment of effector CD8+
T cells and Th1 cells compared to CTX alone, consistent
with the infiltrates found in immune responding
HPV16+ OPSCC human tumors (Fig. 1d). Together,
these observations showed that the combination of CTX
and L-NIL functions as a potent immunomodulatory
regimen capable of multifactorial enhancement of the
intratumoral immune microenvironment.
Immune-suppressive effects of CRT are reversed by CTX/
LNIL immunomodulation
Given the potent immunomodulatory effects induced by
CTX/LNIL treatment, we hypothesized that this
combination could improve the tumor immune micro-
environment, rendering HPV-HNSCC tumors more
responsive to CRT. Thus, we developed a combination
treatment regimen in which mice bearing established
mEER tumors were treated with concurrent CRT and
CTX/L-NIL immunomodulation and we profiled the
tumors for gene expression changes after the first week
of treatment (Fig. 1e). PCA analysis revealed unique
clustering of the combinatory CRT + CTX/L-NIL from
that of CRT alone, but a similar clustering pattern is
noted in comparison of CTX/LNIL and CRT + CTX/
LNIL (Additional file 1: Figure S2A; PC1 explained
43.87% and PC2 explained 18.22% of the observed
(See figure on previous page.)
Fig. 1 CTX / L-NIL reverses the unfavorable immune microenvironment of CRT treated tumors. a-c Subcutaneous established mEER tumors (day
17–18 post tumor cell injection) were treated with tumor-directed radiation (5 X 3Gy) and/or weekly cisplatin (83 μg/mouse) i.p. injections,
according to the schedule in (a); mice were euthanized when tumors reached 225mm2. b Average tumor area (top) and statistical comparison of
tumor sizes at time of first euthanasia (bottom; Tukey’s multiple comparison test). c Survival curves (top) and statistical comparison between
treatments (bottom; Log-rank test); (b and c; N = 1 representative of 2; n = 6–8/group). d Heatmap depicting the relative abundance of various
immune cell populations from CyTOF analysis in HPV16 immune reactive (IR+) and non-reactive (IR-) OPSCC human tumors based on the
presence of HPV16-specific tumor infiltrating lymphocytes (TIL). Frequencies of DC (CD14-HLADR+CD11c+), M1 macrophages (CD163−CD14+HLA-
DR+), monocytic MDCS (mMDSC; CD14+HLADR−), immature B cells (IgM+CD38+CD20+), memory B cells (IgM−CD38−CD20+), total CD4 and CD8+ T
cells, naïve (Tn; CD45RA+CCR7+), central memory (Tcm; CD45RA−CCR7+) and effector memory (Tem; CD45RA−CCR7−) CD4+ and CD8+ T cells,
CD4+CD161+ Tem, CD103+CD161− and CD103+CD161+ CD8+ T cells. Th-denotation in indicates amount of IFNγ (Th1), IL-5 (Th2) and IL-17A (Th17)
produced by the total TIL culture upon phytohemagglutinin stimulation. All data depicted as log-transformed values (base 2) relative to the
median for each individual parameter and each column represents an individual patient (n = 9 total patients). e-f Established mEER tumors were
treated with CRT and/or CTX/L-NIL immunomodulation (CTX at 2 mg/mouse i.p. and L-NIL at 0.2% in drinking water) and total tumor RNA was
extracted and processed for gene expression analysis after 1 week of treatment, according to schedule in (e). f Heatmap of differential immune
gene-set pathway enrichment represented as z-scores between treatment groups (See Additional file 1: Table S3 for immune pathway gene list).
g Gene-set based immune cell type enrichment comparing CRT and CRT + CTX/L-NIL represented as z-scores (left; See Additional file 1: Table S4
for immune cell type gene list) and statistical comparison for each immune cell type (right; unpaired t test); (e and f; N = 1; n = 9/group). *p <
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant
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variance), revealing that CTX/LNIL further modulates
the CRT-induced tumor immune microenvironment.
These data are further supported by immune gene-set
analysis showing that numerous anti-tumor immune
response pathways downregulated by CRT were upregu-
lated by CRT + CTX/L-NIL, including MHC, toll-like re-
ceptor (TLR), complement system, antigen processing,
DC and T cell functions (Fig. 1f; for individual sample
heat map see Additional file 1: Figure S2B). Interestingly,
several immunosuppressive pathways (i.e. iNOS,
hypoxia-adenosine and immune check points) but also
the immunogenic cell death (ICD) pathway that were
upregulated by CRT strongly decreased in expression
after the combinatory treatment. Additional immune cell
type enrichment analyses highlighted a significant in-
crease in several innate immune cell gene subsets fol-
lowing the combinatory CRT + CTX/L-NIL treatment;
however, only inflammatory and plasmacytoid DCs were
significantly upregulated compared to CRT alone (Fig. 1g).
Overall these results show that, at the level of gene expres-
sion, CTX/L-NIL enhances favorable and suppresses un-
favorable intratumoral immunologic effects of CRT.
CRT combined with CTX/L-NIL induces durable control of
established tumors
To determine the therapeutic benefit of CRT and/or
CTX/L-NIL immunomodulation, we assessed tumor
growth and survival (Fig. 2). Briefly, mice bearing estab-
lished mEER tumors were treated with CRT and/or
CTX/L-NIL over a period of two weeks and were then
continually monitored for long-term survival (Fig. 2a).
While CRT and CTX/LNIL treatments alone each in-
duced modest tumor growth delays compared to un-
treated mice, neither promoted complete tumor clearance.
The combination of CRT + CTX/L-NIL significantly
delayed tumor growth compared to singlet treatments and
induced an average of 21% complete tumor clearance
(12.5 to 30% depending on the experiment; Fig. 2b to d).
To further validate these findings and determine if the
treatment benefit was restricted to HPV-positive tumors,
which bear viral antigens and typically have a better
response to CRT, we next assessed the effects of combin-
atory treatments in an aggressive HPV-negative HNSCC
cancer model, MOC2 [36] (Additional file 1: Figure S3).
MOC2 cells were injected subcutaneously in the flank of
mice and treatment was initiated once tumors became
established (approximately 19mm2 in size; Additional file
1: Figure S3A). Combinatory treatment significantly
delayed tumor growth compared to CRT and CTX/LNIL
alone (Additional file 1: Figure S3 B and C) and increased
overall survival by 23 days compared to conventional CRT
(Additional file 1: Figure S3D). Collectively, this dataset
shows that CTX/LNIL immunomodulation enhances the
treatment benefit of conventional CRT regardless of
HPV-status, suggesting that this therapeutic approach
may be applicable to treatment of a variety of solid
tumors.
CTX/L-NIL favorably reprograms the myeloid tumor
microenvironment in CRT treated tumors
We have previously shown that CTX/L-NIL inhibits the
intratumoral infiltration of immunosuppressive MDSCs
[20] and our prior gene expression analysis revealed nu-
merous anti-tumor innate gene-sets and cell types
enriched following CRT + CTX/LNIL treatment com-
pared to CRT alone (Fig. 1f and g). Overall, these obser-
vations suggest that CTX/LNIL immunomodulation may
favorably alter the myeloid tumor microenvironment.
Thus, using flow cytometry, we assessed the impact of
CTX/LNIL and/or CRT treatment on the tumor myeloid
composition and function (Fig. 3). To eliminate immuno-
logic bias due to tumor size, we chose to isolate tumors
and observe the immune response at an intermediate
treatment timepoint (after one week) when tumor sizes
were comparable between all groups (similar to Fig. 1e).
The analysis of myeloid cell subpopulations (among
CD11b+/ CD11c+ cells) was performed using flow
cytometry (for myeloid gating strategy see Additional
file 1: Figure S4A, as previously described in [37]).
Due to the complexity of representing multiple immune
subsets comprehensively, we utilized t stochastic
neighborhood embedding (tSNE) to map high dimen-
sional data onto two dimensional graphs [38]. tSNE ana-
lysis visually demonstrates strong myeloid subtype
variation correlating to treatment (Fig. 3a) and quantifica-
tion of these data shown as Z-scores in the radar plot
highlights this effect (Fig. 3b). Among the subpopulations
assessed, percentages of both inflammatory monocytes
(characterized by the expression of CD11b+, MHCIIlow,
Ly6C+, CCR2+, CX3CR1+, iNOS+ (Additional file 1: Figure
S4B)) and M1-like macrophages were increased following
CTX/LNIL treatment. These two populations are further
increased 2-fold and 1.6-fold, respectively, with CRT +
CTX/LNIL compared to CRT alone (Fig. 3c and d). Fur-
thermore, CRT +CTX/L-NIL significantly reduced the
percentage of the immunosuppressive granulocytic
MDSCs by 2-fold compared to CRT (Fig. 3e). Since both
inflammatory monocytes and M1-like macrophages have
been reported to support anti-tumor immune responses
[39] and granulocytic MDSC are known to be highly im-
munosuppressive, this suggests that CRT +CTX/LNIL
promotes the development of a beneficial myeloid tumor
microenvironment.
Myeloid profiling was also performed in other lymphoid
organs during treatment, in particular draining lymph
nodes (dLNs) and spleen (Additional file 1: Figure S5). In
the dLNs, CRT + CTX/L-NIL promoted a 2.8-fold de-
crease in granulocytic MDSCs compared to CRT
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(Additional file 1: Figure S5 C), however, no other notable
changes among myeloid subsets were observed in dLNs
and spleen (Additional file 1: Figure S5 A-H). This suggests
that the effects induced by the combinatory treatment are
strongly localized to the tumor microenvironment. Overall,
these observations demonstrate that CTX/L-NIL immuno-
modulation can be combined with CRT to favorably repro-
gram the tumor myeloid microenvironment, increasing cell
subtypes known to benefit anti-tumor immune responses
(inflammatory monocytes and M1-like macrophages) and
decreasing immunosuppressive cell subsets (granulocytic
MDSCs).
Improved myeloid tumor microenvironment facilitates
CD8+ T cell cytotoxic response
Since myeloid cells can both promote and suppress T
cells according to their subtype and activation status
[40], we sought to determine whether the favorable shift
in the myeloid microenvironment induced by combin-
atory treatment influenced T cell anti-tumor cytotoxicity.
Fig. 2 CTX/L-NIL combines with CRT to induce durable control of established tumors. Mice bearing established mEER tumors were treated with
CRT (10 X 3Gy tumor-directed radiation and 83 μg/mouse weekly cisplatin i.p.) and/or CTX/L-NIL immunomodulation (CTX at 2 mg/mouse i.p. and
L-NIL at 0.2% in drinking water) according to the schedule in (a); mice were euthanized when tumors reached 225mm2. b Individual tumor
growth curves shown by treatment group, with each mouse represented as a single line. c Average tumor area (top) and statistical comparison at
time of first euthanasia (bottom; Tukey’s multiple comparison test). d Survival curves (top) and statistical comparison between treatments
(bottom; Log-rank test). (b-d; N = 1 representative of 2; n = 8–9/group). **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant
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Fig. 3 (See legend on next page.)
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To assess this, we performed an ex vivo CD8+ T cell
cytotoxic assay in which naïve splenic CD8+ T cells were
stimulated (using anti-CD3, anti-CD28, and IL-2) in the
presence of myeloid cells (CD11b+ and CD11c+ cells)
isolated from treated tumors (as previously described
in [32]). The myeloid-primed and stimulated CD8+ T
cells were then co-cultured with mEER tumor cells
and assessed for T cell induced cytotoxicity using
Annexin-V/PI staining (Fig. 3f). Microscopic examination
of Annexin V showed an increase in tumor cell apoptosis
after CRT + CTX/L-NIL treatment compared to single
therapies (Fig. 3g). Quantitative flow cytometry analysis
revealed a significant improvement in the CD8+ T cell
cytotoxicity, compared to non-primed stimulated CD8+ T
cells, when influenced by the CRT +CTX/L-NIL intratu-
moral myeloid compartment (Fig. 3h). These data suggest
that the favorable myeloid shift induced with the combin-
ation of CRT and CTX/LNIL lends to enhanced CD8+ T
cell cytotoxicity.
CTX/LNIL improves the T cell tumor microenvironment in
CRT treated tumors
Based on the above data and our previous report show-
ing that CTX/LNIL immunomodulation promotes CD8+
T cell tumor infiltration [20], we assessed whether CTX/
LNIL and/or CRT could favorably alter the intratumoral
lymphoid compartment using multi-color immunofluor-
escence and flow cytometry (Figs. 4 and 5). After one
week of treatment (similar to Fig. 1e) we profiled tumors
by multiplex immunofluorescence [31]. We observed an
increase in CD8+ T cell tumor infiltration and a higher
level of cytoplasmic Granzyme B after CTX/L-NIL and
combinatory treatment (Fig. 4a). Image quantification of
T cell subsets further revealed that CTX/LNIL immuno-
modulation promoted a CD8+ T cell dominated tumor
and a drastic depletion of Tregs, and this effect was
maintained when combined with CRT (Fig. 4b). Add-
itionally, we observed that CTX/LNIL improved CD8+ T
cell activation compared to CRT, as evidenced by the
expression of cytoplasmic Granzyme B. When com-
bined, although non-significantly, CRT + CTX/L-NIL
induces a 4-fold increase in the intratumoral density of
CD8+ T cells expressing Granzyme B compared to CRT
alone (Fig. 4c).
To further characterize the influence of combinatory
treatment on changes within the T cell tumor micro-
environment, we performed flow cytometry (for lympho-
cyte gating strategy see Additional file 1: Figure S6A).
tSNE analysis revealed qualitative shifts of intratumoral
T cell subsets correlating to treatment (Fig. 5a). Further
quantification revealed a 1.8-fold increase in the percent-
age of CD8+ T cells and a 3.4-fold decrease in Tregs
after the combinatory CRT + CTX/LNIL treatment com-
pared to CRT alone (Fig. 5b). These changes resulted in
a 31.8-fold increase in the CD8+ T cell/Treg ratio after
CRT + CTX/L-NIL compared to CRT alone (Fig. 5c).
Further T cell subset analysis in other lymphoid organs
demonstrated that the combinatory CRT + CTX/L-NIL
treatment also reduced the percentage of Tregs in the
dLNs (Additional file 1: Figure S7C) but not in the
spleen (Additional file 1: Figure S7G) compared to CRT
alone. The percentage of CD8+ and CD4+ T cells in
dLNs (Additional file 1: Figure S7A and B) and spleen
(Additional file 1: Figure S7E and F) were unchanged
and thus the ratio of CD8+ T cells / Tregs was only sig-
nificantly increased in dLNs but not in the spleen after
CRT + CTX/L-NIL therapy compared to CRT alone
(Additional file 1: Figure S7 D and H). Overall these data
suggest that the combination of CRT and CTX/LNIL
strongly and specifically activates the intratumoral T cell
microenvironment.
CRT + CTX/L-NIL changes the phenotype of tumor-
infiltrating CD8+ T cells
To further understand the consequences of the improved
CD8+ T cell infiltration induced by the combinatory treat-
ment, we next analyzed the tumor-infiltrating CD8+ T
cells for various functional markers. We first tested
(See figure on previous page.)
Fig. 3 CRT + CTX/L-NIL reprograms the myeloid tumor microenvironment. Established mEER tumors were treated with CRT and/or CTX/L-NIL and
harvested after the first week of treatment, as shown in to Fig. 1e, and tumor myeloid cell infiltrate was analyzed using flow cytometry (a-e; see
Additional file 1: Figure S4 for myeloid flow cytometry gating strategy) and ex vivo co-culture (f-h). a Myeloid-focused tSNE (among CD11b+/
CD11c+ cells) from flow cytometry data for each treatment group. b Corresponding tSNE color-map (left) and radar plot (right) showing myeloid
sub-type alterations between each treatment group as z-scores (myeloid sub-type color in radar plot corresponds with their color in tSNE map; N
= 1 representative of 3; n = 8–9/group). c-e Percentage of myeloid sub-types among total myeloid cell tumor infiltrate (CD11b+/CD11c+),
including inflammatory monocytes (c), M1-like macrophages (d), and granulocytic MDSCs (e) (N = 3; n = 23–25/group; Tukey’s multiple
comparison test for inflammatory monocytes and Dunn’s multiple comparison test for M1-like macrophages and granulocytic MDSCs). f
Experimental schematic used to test treatment-induced myeloid influence on CD8+ T cell cytotoxicity. Naïve splenic CD8+ T cells were stimulated
with anti-CD3/CD28 antibodies and IL-2 in the absence or presence of myeloid cells (CD11b+ and CD11c+ cells) isolated from tumors that
received different treatments for 3 days and then co-cocultured with mEER cells in presence of IL-2. After 24 h, apoptotic tumor cells were
detected by Annexin V/ PI staining. g Representative images of mEER tumor cells stained for Annexin V (shown in green) following co-culture
(scale bars show 200 μm). h mEER tumor cell apoptotic fold change (Annexin V+ / PI−) normalized to non-primed T cells (T cells not co-cultured
with myeloid cells) (N = 4; n = 20–26/group; Dunn’s multiple comparison test). All bar graphs show mean +/− SD and each dot represents an
individual mouse. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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whether CRT + CTX/L-NIL could improve CD8+ T cell
tumor specificity by evaluating E7-specific tetramers bind-
ing by flow cytometry (Additional file 1: Figure S6B). This
revealed that the proportion of intratumoral CD8+ T cells
specific for the E7 antigen expressed by mEER tumor cells
was significantly increased following CRT +CTX/LNIL
treatment (more than 22.7% of CD8+ T cells on average)
(Fig. 5d). Based on a consensus nomenclature defined for
murine and human CD8+ T cell phenotypes [41], we
monitored the expression of several markers associated
with T cell effector, memory, and exhaustion functions
using flow cytometry (Fig. 5e and Additional file 1: Figure
S8). CRT + CTX/L-NIL promoted a significant increase in
the expression of killer cell lectin-like receptor G1
(KLRG1), a marker commonly associated with effector
CD8+ T cell subsets [42]. However, perforin expression on
CD8+ T cells was significantly decreased after CRT +
CTX/L-NIL treatment compared to CRTalone, suggesting
Fig. 4 CRT + CTX/L-NIL promotes intratumoral CD8+ T cell infiltration and activation. Established mEER tumors were treated with CRT and/or CTX/
L-NIL and harvested after the first week of treatment, as shown in Fig. 1e, and tumor lymphocyte infiltrate was analyzed using quantitative
multiplex immunofluorescence (qmIF; a-c). a Representative multiplex images of mEER tumors showing DAPI (nuclei, dark blue), EpCAM (tumor,
red), CD8α (CD8+ T cells, cyan), and Granzyme B (T cell cytotoxic marker, green). b Pie-charts showing T cell subset fractions among total T cells
for each treatment (fraction averaged across 5 images per tumor and n = 3/group). c Log2 fold change of Granzyme B (GzB)
+ CD8+ cells
normalized to control group (N = 1; n = 3/group; Tukey’s multiple comparison test). Bar graphs show mean +/− SD. *p < 0.05; **p < 0.01
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that CD8+ T cells had entered a later killing phase [43].
Collectively, these observations show that the tumor infil-
trating CD8+ T cells promoted by the combinatory CRT +
CTX/LNIL treatment exhibit improved specificity and ef-
fector phenotypes compared to CRT alone.
Tumor growth inhibition induced by CRT + CTX/LNIL is
dependent on CD8+ T cells
Since our data show that CTX/L-NIL immunomodula-
tion enhances susceptibility of immune-refractory tu-
mors to CRT by changing the myeloid compartment,
leading to enhancements in CD8+ T cell specificity and
function, we examined whether improved tumor
regression and survival was dependent on CD8+ T cells
(Fig. 6). To accomplish this, depleting anti-mouse CD8
antibodies were injected two days before treatment and
then weekly over the course of CRT + CTX/LNIL treat-
ment (Fig. 6a). Flow cytometry analysis validated the de-
pletion of CD8+ T cells observed in the blood (Fig. 6b).
In the absence of CD8+ T cells, the combinatory treat-
ment induced a small tumor growth delay, compared to
control tumors (Fig. 6c and d). The stall in tumor
growth observed in the absence of CD8+ T cells is likely
a combination of direct tumor cell killing by the chemo-
therapeutic and radiation components of the combin-
ation treatment and non-CD8-dependent cytotoxic
Fig. 5 CRT + CTX/L-NIL enhances the lymphoid tumor microenvironment. Established mEER tumors treated with CRT and/or CTX/L-NIL and were
harvested similar to Fig. 1e, and tumor lymphocyte infiltrate was assessed using flow cytometry (a-e; see Additional file 1: Figure S6 for lymphocyte
flow cytometry gating strategy). a Lymphoid-focused tSNE (among TCRβ+ cells) from flow cytometry data for each group of treatment (left) and
corresponding color-map (right) with colored lymphocyte subsets listed below (N= 1 representative of 5; n = 8–9/group). b Percentage of lymphoid
sub-types among total tumor infiltrating T cells (TCRβ+ cells), including CD8+ T cells (top right), CD4+ T cells (bottom left) and regulatory T cells
(bottom right) (N = 3–4; n = 23–36/group; Tukey’s multiple comparison test for CD8+ T cells and Dunn’s multiple comparison test for CD4+ and
regulatory T cells). c Ratio of CD8+ T cells/ regulatory T cells percentages (N = 3; n = 23–24/group; Dunn’s multiple comparison test). d Percentage of
E7-Tetramer+ among CD8+ T cells (N = 5; n = 33–37/group; Dunn’s multiple comparison test). e Representative flow cytometry histograms showing
KLRG-1 expression among CD8+ T cells expressed as the % of the maximum count (left) and cumulative median fluorescence intensity (MFI) for each
treatment group (right). FMO (Fluorescence minus one) is a mixture of all antibodies permitting CD8+ T cell identification without the phenotypical
marker of interest (N = 2, n = 12; Tukey’s multiple comparison test). All bar graphs show mean +/− SD and each dot represents an individual mouse.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Fig. 6 Tumor growth inhibition induced by CRT + CTX/L-NIL requires CD8+ T cells. Established mEER tumors were treated with CRT + CTX/L-NIL and
anti-CD8α depleting antibody, or isotype control antibody, according to the schedule in (a); mice were euthanized when tumors reached 225mm2.
b CD8+ T cell percentages among total viable cells in the blood at day 29 of treatment as assessed by flow cytometry (N = 1; n = 10/group, each as
an individual dot; data are means +/− SD; Mann-Whitney test). c Individual tumor growth curves shown by treatment group, with each mouse
represented as a single line. d Average tumor area (top) and statistical comparison at time of first euthanasia (bottom; Tukey’s multiple comparison
test). e Survival curves (top) and statistical comparison between treatments (bottom; Log-rank test). (c-e; N = 1 representative of 2; n = 10/group).
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant
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mechanisms (e.g. Natural Killer-mediated killing).
Nevertheless, long term survival benefits are entirely lost
in the absence of CD8+ T cells (Fig. 6e). These results
confirm that CD8+ T cells are critical component of the
therapeutic benefit induced by the combinatory CRT +
CTX/LNIL treatment.
Discussion
Enhancing the efficacy of standard-of-care therapies,
such as CRT, is a critical goal in the field of oncology. In
HPV-associated HNSCC, treatment response has been
correlated with tumor immune cell infiltration [5]. Add-
itionally, CRT induces immunosuppressive effects which
potentially limit its effectiveness [12, 13]. Thus, we hy-
pothesized that therapeutic outcome of CRT could be
improved through favorable modulation of the tumor
immune microenvironment.
The multi-faceted immunosuppressive tumor micro-
environment contains numerous potential therapeutic
targets whose modulation could render the tumor
microenvironment more immunologically favorable. In-
deed, HNSCC tumors express various immunosuppres-
sive cytokines such as transforming growth factor beta
(TGF-β), IL-6 or IL-10 [44, 45] and enzymes which
deprive the tumor microenvironment of essential
nutrients for T cell function, such as indoleamine
2,3- dioxygenase (IDO)-mediated degradation of the
amino acid tryptophan [46]. Several IDO inhibitors
are currently in phase I/II clinical trials [47] and
may constitute an effective immunomodulatory
therapy to combine with CRT. Additionally, MDSCs
were found to be present in high numbers in
HNSCC tumors [48] and their enzymes, arginase-1
and iNOS, are known to drive immunosuppression
partially by inactivating effector T cells [49, 50].
Small molecule inhibitors have been developed to
target arginase-1 and iNOS, including nor-NOHA
and L-NIL, respectively [51]. iNOS, in particular, has
been shown to be overexpressed in many different
solid tumors and implicated in both immunosup-
pressive responses and resistance to chemotherapy
and radiotherapy [52, 53], which support the ration-
ale for combining an iNOS inhibitor with
standard-of-care CRT. We have previously shown
that while iNOS inhibition using L-NIL can inhibit
MDSC recruitment to the tumor, this compound also
drives a compensatory increase in Treg infiltration.
This is addressed through a combination immuno-
modulatory approach combining L-NIL with CTX,
which promotes significant antitumor immune
effects by depleting intratumoral MDSCs and Tregs,
respectively [20]. Herein, our ultimate goal was to
determine if CTX/L-NIL immunomodulation could
reverse CRT-induced immunosuppressive effects and
enhance antitumor effector responses, thus maximiz-
ing its treatment efficacy.
Toward this end, we developed a clinically relevant
treatment model based on standard-of-care CRT admin-
istrated to patients with HPV-HNSCC. In this model, we
treated the syngeneic HPV-HNSCC mEER tumor line
with fractionated (10 fractions of 3 Gy) tumor-directed
radiation regimen and weekly cisplatin administration.
This regimen is particularly important because different
radiation schedules can induce drastically distinct
immunologic responses and may even suppress immun-
ity [14, 54]. Much of the preclinical literature studying
CRT effects uses “hypo-fractionated” (small number of
large doses) RT treatment schedules and shows a delay
in tumor growth as well as an increased infiltration of
innate and adaptive cells, such as DCs and CD8+ T cells
in the tumor [55]. However, the infiltration of
anti-tumor immune cells following hypo-fractionated ra-
diation has also been shown to be temporally restricted
and to occur primarily between 5 to 10 days after the
first irradiation [55, 56]. We have also assessed the
tumor immune response at various time points following
our more conventionally fractionated regimen of CRT
and observed that the tumor infiltration of DCs, CD8+
and CD4+ T cells reached a maximum after one week of
treatment (data not shown). Our observation showed
that fractionated radiation presents a timely restricted
immune response similar to hypo-fractionated regimens,
and the date we selected for analyzing the tumor micro-
environment was during this peak window of immune
cell infiltration. In addition to the clinical relevance of
our selected treatment schedule, we also chose to assess
the effects of therapeutic approaches in large, established
tumors. This more accurately represents the clinical
scenario, in which patients often present with advanced
tumors which already have well-established immunosup-
pressive microenvironments. Thus, our data should pro-
vide a translationally-relevant understanding of the
immunologic consequences of CRT as well as actionable
therapeutic strategies for overcoming the immunological
barriers.
Herein, we showed that CTX/L-NIL immunomodula-
tion combined with CRT promoted significant enhance-
ment of treatment efficacy, with 21% complete tumor
rejection in a CD8-dependent manner. In tumors of
mice receiving the combinatory treatment, we observed
significant changes in the myeloid immune microenvir-
onment, including an increase in various myeloid popu-
lations known to promote anti-tumor effects (i.e.
inflammatory monocytes and M1-like macrophages) and
a decrease in immunosuppressive granulocytic MDSCs.
This modification in the myeloid microenvironment
likely contributes to an improved T cell compartment
within the tumor, including an increase in the ratio
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CD8+ T cells/regulatory T cells and in the percentage of
E7-specific CD8+ T cells compared to CRT alone. Gene
expression analysis further corroborated these effects as
it showed that CRT + CTX/L-NIL upregulated gene sets
related to MHC, antigen processing, dendritic cell func-
tion, and induced a “hot” (activated) intratumoral im-
munologic state. Moreover, the analysis of tumor gene
expression showed an increase in immunologic cell
death (ICD) pathway compared to control group for
each of singlet therapies (CRT or CTX/L-NIL), suggest-
ing that these treatments favor ICD. Surprisingly, the
ICD pathway appears to be decreased following the
combination of CRT + CTX/L-NIL compared to singlet
treatments, suggesting that induction of immunogenic
cell death is not the major mechanism contributing to
the efficacy of the combinatory treatment. Overall, our
results demonstrated that CTX/LNIL immunomodula-
tion can greatly improve the treatment effects of CRT by
heating up the tumor immune microenvironment
(Fig. 7), towards a similar constitution that in the clinic
has been associated with a favorable response to
(chemo) radiotherapy (Fig. 1d and [28]).
While CD8+ T cell phenotype profiling showed an in-
crease in markers of T cell memory, tumor rechallenge
experiments revealed a lack of functional immunologic
memory response (data not shown). This constitutes a
limitation of our results and mandates further investiga-
tion to understand and address this limitation in
long-term memory recall response. A number of recent
studies suggest that radiation fractionation schedules
may have significant treatment implications on the
anti-tumor functionality of the immune system. Previous
Fig. 7 CTX/L-NIL immunomodulation renders the tumor microenvironment receptive to CRT. Schematic abstract: The tumor immune microenvironment
(both myeloid and lymphoid compartments) remains “cold” after CRT treatment, and is characterized by the infiltration of granulocytic MDSCs and
regulatory T cells. However, the combination of CRT with CTX/L-NIL reverses these immunosuppressive effects and further promotes increases in M1-like
macrophages and inflammatory monocytes in the tumor. This favorable myeloid alteration likely plays a role in the improved intratumoral CD8+ T cell
response, which shows enhanced specificity, effector and memory phenotypes
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work has shown that hypofractionated radiation sched-
ules can increase the frequency of circulating T cells,
and promote higher numbers of CD8+ T cells [57, 58].
Thus, future work will compare the immunologic conse-
quences, especially those pertaining to immunologic
memory, of different radiation fractionation schedules.
Our work also suggests that immune microenvironment
modulation could be utilized to improve treatment re-
sults of other immunotherapeutic approaches (i.e. im-
mune checkpoint inhibitors, chimeric antigen receptor
T cells, cancer vaccination strategies). This could poten-
tially improve the memory response induced by our
combination treatment, since immune checkpoint block-
ade with anti-CTLA-4 has been shown to enhance the
generation of memory T cells in mice [59]. It is also
likely that additional strategies to improve the number
of HPV-E6/E7 specific CD8+ T cells, such as vaccination
with long peptides against these antigens, could also im-
prove the overall treatment benefit of this regimen [60].
In an effort to enhance the translatability of this work,
we utilized a repurposing approach using two
clinically-relevant drugs to overcome the negative effects
of the tumor immune microenvironment. This combin-
ation included CTX, a widely utilized chemotherapeutic
agent which is commonly used as an immunomodulator;
and L-NIL, which has been tested in clinical trials for
asthma and inflammatory diseases [19]. Despite the
translational potential of this study, a few key issues re-
main to be addressed before clinical investigation of the
CTX/LNIL immunomodulatory regimen. The first re-
lates to the injection timing and the dose of CTX used,
as this can have major influences on treatment response.
Contrary to high dose CTX, which is lymphodepleting
and cytotoxic, low dose of CTX is immune dependent,
increases the anti-tumor immune response and favors T
cell tumor infiltration [61]. In terms of treatment sched-
ule, metronomic dosing has been previously tested in
the clinic and was found to selectively deplete Tregs and
improve overall T cell function and specificity [62, 63].
However, another study demonstrated optimal immuno-
modulating effects with a single injection of CTX
slightly above the ablative dose [64]. Thus, a CTX dose
titration and schedule-finding study would likely be ne-
cessary to establish the optimal immunomodulatory
response. The second key issue relates to the iNOS
inhibitor utilized in this study, L-NIL, which, despite
prior testing in clinical trials for benign diseases, re-
quires additional clinical assessment before it could be
used for treatment of cancer patients. However, the
efficacy of other commonly used drugs with iNOS inhi-
biting activity, such as doxycycline or phosphosdiester-
ase 5 inhibitors (sildenafil and tadalafil), could be
investigated in parallel to facilitate rapid translation to
clinic trials [65–67].
Conclusion
In conclusion, our study demonstrates that immunomo-
dulation of the tumor microenvironment can render
refractory tumors susceptible to CRT. The clinical rele-
vance of the models studied and the combination of
standard-of-care CRT with repurposed immunomodula-
tory drugs has the potential to accelerate clinical transla-
tion of this approach.
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